期刊文献+

CRISPR/Cas9技术在单纯疱疹病毒研究中的应用

Application of CRISPR/Cas9 technology in the study of herpes simplex virus
原文传递
导出
摘要 单纯疱疹病毒(herpes simplex virus,HSV)是导致人类疱疹性疾病的主要病原体,具有广泛宿主细胞类型、庞大外源基因容量等特点,因此也是一种颇具吸引力的病毒载体。HSV基因组较为庞大,对于病毒基因组的操作技术便成为关键环节。对该病毒基因组的操作先后经历了同源重组(homologous recombination),细菌人工染色体技术(bacterial artificial chromosome,BAC)和CRISPR/Cas9(clustered,regularly interspaced,short palindromic repeat/CRISPR-associated nuclease 9)技术。同源重组具有重组效率低、产物不易纯化等缺点,而且将大型病毒基因组克隆到BAC上是一个耗时耗力的过程。近年来,CRISPR/Cas9技术因其操作简便、重复性好、成本低廉等优势而被越来越多的研究者应用于各种物种的基因工程研究工作中,对于病毒基因组的操作也随之更加精确高效。本文对CRISPR/Cas9技术在HSV基因功能、治疗HSV感染性疾病及HSV载体研究中的应用进行综述,以期对相关的研究工作提供一定参考。 Herpes simplex virus(HSV),the main pathogen of human herpetic diseases,is an attractive viral vector due to a wide range of host cell types and a large capacity of foreign gene.The manipulation on herpes simplex virus genome,up to 152 kb,has been the key process and has undergone the improvement from homologous recombination to bacterial artificial chromosome(BAC)and CRISPR/Cas9.However,homologous recombination is imperfect because the efficiency of recombination is relatively low and the product is too complex to purify.Construction of recombinant HSV based on BAC is time-and labor-consuming.Currently,CRISPR/Cas9 has been applied to genetic engineering of various species by more and more researchers due to its convenience,good repeatability,low cost,and then the manipulation of viral genome is more accurate and efficient.Application of CRISPR/Cas9 in the research of HSV gene function,HSV infection therapy and viral vector were summarized in this review,in order to provide reference for corresponding research.
作者 仇桂芳 苏文浩 卫江波 Qiu Guifang;Su Wenhao;Wei Jiangbo(Herpesvirus Research Group,National Vaccine and Serum Institute,Beijing 101111,China)
出处 《中华微生物学和免疫学杂志》 CAS CSCD 北大核心 2021年第8期656-660,共5页 Chinese Journal of Microbiology and Immunology
关键词 单纯疱疹病毒 基因工程 CRISPR/Cas9 Herpes simplex virus Gene engineer CRISPR/Cas9
  • 相关文献

参考文献2

二级参考文献17

  • 1王伟国,薛惠斌,苏长青,崔贞福,聂明明,Jonathan Sham,吴孟超,钱其军.基因-病毒治疗系统CNHK200-hA对肺癌治疗的研究[J].中华肿瘤杂志,2005,27(2):69-72. 被引量:9
  • 2王振发,王烈,卫立辛.基因治疗病毒载体的研究进展[J].医学综述,2007,13(7):490-492. 被引量:11
  • 3Benencia F,Courreges MC,Fraser NW,Coukos G.Herpes virus oncolytic therapy reverses tumor immune dysfunction and facilitates tumor antigen presentation.Cancer Biol Ther,2008,7:1194-1205.
  • 4Clive KS,Tyler JA,Clifton GT,et al.Use of GM-CSF as an adjuvant with cancer vaccines: beneficial or detrimental? Expert Rev Vaccines,2010,9:519-525.
  • 5Israyelyan A,Chouljenko VN,Baghian A,et al.Herpes simplex virus type-1 (HSV-1) oncolytic and highly fusogenic mutants carrying the NV1020 genomic deletion effectively inhibit primary and metastatic tumors in mice.Virol J,2008,5:68.
  • 6Cinatl J Jr,Cinatl J,Michaelis M,et al.Potent oncolytic activity of multimutated herpes simplex virus G207 in combination with vincristine against human rhabdomyosarcoma.Cancer Res,2003,63:1508-1514.
  • 7Liu BL,Robinson M,Han ZQ,et al.ICP34.5 deleted herpes simplex virus with enhanced oncolytic,immune stimulating,and anti-tumour properties.Gene Ther,2003,10:292-303.
  • 8Bateman AR,Harrington KJ,Kottke T,et al.Viral fusogenic membrane glycoproteins kill solid tumor cells by nonapoptotic mechanisms that promote cross presentation of tumor antigens by dendritic cells.Cancer Res,2002,62:6566-6578.
  • 9Fu X,Zhang X.Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype.Cancer Res,2002,62:2306-2312.
  • 10Ebert O,Shinozaki K,Kournioti C,etal.Syncytia induction enhances the oncolytic potential of vesicular stomatitis virus in virotherapy for cancer.Cancer Res,2004,64:3265-3270.

共引文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部